<DOC>
	<DOC>NCT00048204</DOC>
	<brief_summary>A Placebo Controlled Study Evaluating Efficacy And Safety of Medication In Patients With Major Depressive Disorder (MDD)</brief_summary>
	<brief_title>A Study Of A New Medicine (GW597599B) For The Treatment Of Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Paroxetine</mesh_term>
	<mesh_term>Vestipitant</mesh_term>
	<criteria>Patients meet the diagnosis of Major Depressive Disorder (MDD). Patients with a primary diagnosis other than MDD. Patients with a history of schizophrenia, schizoaffective disorders, seizure disorders or bipolar affective disorder. Patients receiving formal psychotherapy or cognitive/behavioral therapy concurrently or in the 12 weeks prior to screening visit. Patient is actively suicidal. Patients who have a history of migraine headaches.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Depression</keyword>
	<keyword>Psychiatry</keyword>
	<keyword>Major Depressive Disorder</keyword>
</DOC>